Redmile Group LLC Has $7.12 Million Stock Position in Insulet Corporation $PODD

Key Points

• Redmile Group LLC has significantly increased its holdings in Insulet Corporation by 183.6%, owning over 27,000 shares valued at approximately $7.12 million.
• Insulet reported Q1 earnings of $1.17 EPS, beating estimates by $0.25, with a revenue increase of 32.9% year-over-year.
• Numerous analysts have upgraded Insulet's stock ratings, with Jefferies maintaining a "buy" rating and Wells Fargo raising the price target from $330 to $350.

Redmile Group LLC grew its stake in Insulet Corporation (NASDAQ:PODD - Free Report) by 183.6% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 27,109 shares of the medical instruments supplier's stock after buying an additional 17,550 shares during the period. Redmile Group LLC's holdings in Insulet were worth $7,119,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Larson Financial Group LLC lifted its position in shares of Insulet by 426.3% in the first quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier's stock worth $26,000 after buying an additional 81 shares during the last quarter. Zions Bancorporation National Association UT bought a new position in shares of Insulet in the first quarter worth about $26,000. SouthState Corp increased its stake in shares of Insulet by 253.3% in the first quarter. SouthState Corp now owns 106 shares of the medical instruments supplier's stock worth $28,000 after purchasing an additional 76 shares during the period. Ramirez Asset Management Inc. bought a new position in shares of Insulet in the first quarter worth about $53,000. Finally, Golden State Wealth Management LLC increased its stake in shares of Insulet by 553.1% in the first quarter. Golden State Wealth Management LLC now owns 209 shares of the medical instruments supplier's stock worth $55,000 after purchasing an additional 177 shares during the period.

Insulet Price Performance

Shares of PODD stock traded up $1.96 during trading hours on Friday, hitting $348.43. The company had a trading volume of 498,473 shares, compared to its average volume of 584,368. The firm has a market capitalization of $24.53 billion, a price-to-earnings ratio of 105.91, a PEG ratio of 2.90 and a beta of 1.36. Insulet Corporation has a 12 month low of $211.27 and a 12 month high of $350.00. The firm's fifty day moving average is $307.55 and its 200 day moving average is $289.82. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26.

Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.25. The firm had revenue of $649.10 million for the quarter, compared to the consensus estimate of $612.31 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The business's revenue for the quarter was up 32.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.55 EPS. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, sell-side analysts predict that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on PODD shares. Wall Street Zen upgraded Insulet from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Sanford C. Bernstein reiterated an "outperform" rating on shares of Insulet in a research note on Friday, May 16th. Canaccord Genuity Group lifted their price objective on Insulet from $331.00 to $353.00 and gave the stock a "buy" rating in a research note on Friday, August 8th. The Goldman Sachs Group began coverage on Insulet in a research note on Friday, May 30th. They issued a "buy" rating and a $380.00 price objective on the stock. Finally, Morgan Stanley restated an "overweight" rating on shares of Insulet in a research note on Thursday, August 7th. Sixteen research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $332.71.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.